Skip to Main Content

Paper Details

Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib.
Leuk Res
26
2019
Author NameAffiliation
Michael W DeiningerHuntsman Cancer Institute, University of Utah
Moshe TalpazComprehensive Cancer Center, University of Michigan, 1500 East Medical Center Dr ann arbor
  • 1 - 2

Datasets

Release 1.2